DJIA 16,960.57 -123.23 -0.72%
NASDAQ 4,449.56 -22.54 -0.50%
S&P 500 1,978.34 -9.64 -0.48%
market minute promo


23.17 0.12 (0.52%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

TKPYY $23.17 0.52%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $23.15
Previous Close $23.05
Daily Range $23.14 - $23.20
52-Week Range $21.64 - $25.09
Market Cap $36.6B
P/E Ratio 0.00
Dividend (Yield) $0.00 (3.3%)
Volume 15,329
Average Daily Volume 27,809
Current FY EPS $0.71





News & Commentary

JPMorgan Healthcare Conference Highlights: Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals takes the stage to highlight Belviq, other lorcaserin indications, and its remaining pipeline. Do investors have a reason to be excited?

JPMorgan Healthcare Conference Highlights: Pharmacyclics, Inc.

The JPMorgan Healthcare Conference kicks off and Pharmacyclics dishes new pricing and duration data on key drug Imbruvica.

Why Sucampo Pharmaceuticals, Inc. Shares Popped

Sucampo's 8-K filing with the SEC delivers a nice surprise to shareholders.

10 Countries With the Longest Life Expectancy

These are the 10 countries with the longest life expectancy. See what factors have allowed their citizens to live longer as well as how you might be able to benefit from their longevity.

Another High-Profile Diabetes Candidate Goes Down

With Takeda's recent setback, Big Pharma's diabetes cupboard is looking very bare.

FDA Takes Issue with Takeda's Prospective 2014 Approval of Vedolizumab

Concerns over infection risks spurred action from an FDA advisory panel regarding the approval of the inflammatory bowel disease treatment vedolizumab.

Mood-Altering News From the Pharma Space

Big Pharma falters again, while an underrated CNS specialist delivers a new, better, drug

Will These Obesity Treatments Cause Your Portfolio to Lose Weight?

Is there any hope left for VIVUS, Arena, and Orexigen -- three obesity treatment stocks that increasingly appear to be addressing a demand that simply isn’t there?

Takeda’s 3,000 Bladder Cancer Lawsuits: 2 Down, …

Diabetes Drugmakers and Their "Definitely Maybe" Moment

A long-awaited safety data on a popular class of type 2 diabetes drugs sends mixed messages to doctors and investors.

See More TKPYY News...